Gabriele Martelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gabriele Martelli has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Roberto Agresti
Breast Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan, Italy
11 shared publications - Maria Grazia Daidone
Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
8 shared publications - Cristina Ferraris
Breast Unit, Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
7 shared publications - Ilaria Maugeri
Breast Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
7 shared publications - Patrizia Boracchi
University of Milan
6 shared publications Domenico Piromalli
Breast Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
4 shared publications
Latest Publications
- 18 November 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2255-2266
Sentinel Node Biopsy Alone Versus Sentinel Node Biopsy Plus Axillary Dissection in cT2 cN0/1 Breast Cancer After Neoadjuvant Chemotherapy: 15-Year Results of a Prospective Interventional Study
Recent guidelines recommend sentinel lymph node biopsy (SNB) of cN1 breast cancer when the axilla is clinically clear after neoadjuvant chemotherapy (NAC).
- 18 November 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2255-2266
Sentinel Node Biopsy Alone Versus Sentinel Node Biopsy Plus Axillary Dissection in cT2 cN0/1 Breast Cancer After Neoadjuvant Chemotherapy: 15-Year Results of a Prospective Interventional Study
Recent guidelines recommend sentinel lymph node biopsy (SNB) of cN1 breast cancer when the axilla is clinically clear after neoadjuvant chemotherapy (NAC).
- 15 November 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2326-2327
ASO Author Reflections: No Further Axillary Treatment is Safe if the Sentinel Nodes are Negative After Neoadjuvant Chemotherapy in cT2 cN1 Breast Cancer
- 15 November 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2326-2327
ASO Author Reflections: No Further Axillary Treatment is Safe if the Sentinel Nodes are Negative After Neoadjuvant Chemotherapy in cT2 cN1 Breast Cancer
- Open Access
- 1 December 2023
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 158 (12) , 1275-1284
Prophylactic Salpingo-Oophorectomy and Survival After BRCA1/2 Breast Cancer Resection
Importance: Few studies have investigated whether prophylactic salpingo-oophorectomy (PSO) for patients with previously resected breast cancer who carry pathogenic germline BRCA1 or BRCA2 variants is associated with a reduced risk of cancer-specific death.Objective: To assess the association of PSO and prophylactic mastectomy (PM) with prognosis after quadrantectomy or mastectomy as primary treatment for patients with BRCA1 or BRCA2 breast cancer.Design, Setting, and Participants: This retrospective cohort study was performed in a single-institution, tertiary referral center. Consecutive patients with invasive breast cancer treated surgically between 1972 and 2019 were recruited and followed up prospectively after they were found to carry the BRCA1 or BRCA2 gene variant. The data analysis was performed between April 2022 and July 2023.Exposure: Following breast surgery, some patients underwent PSO, PM, or both, whereas others did not.Main Outcomes and Measures: The primary study end point was overall survival as measured by the Kaplan-Meier method. Secondary end points were crude cumulative incidence of breast cancer–specific mortality, ipsilateral breast tumor recurrence (IBTR), contralateral breast cancer, ovarian cancer, and ovarian cancer–specific mortality.Results: Of 480 patients included in the cohort (median age at initial surgery, 40.0 years; IQR, 34.0-46.0 years), PSO was associated with a significantly reduced risk of death (hazard ratio [HR], 0.40; 95% CI, 0.25-0.64; P < .001). This reduction was most evident for patients carrying the BRCA1 variant (HR, 0.35; 95% CI, 0.20-0.63; P = .001), those with triple-negative disease (HR, 0.21; 95% CI, 0.09-0.46; P = .002), and those with invasive ductal carcinoma (HR, 0.51; 95% CI, 0.31-0.84; P = .008). Prophylactic salpingo-oophorectomy was not associated with risk of contralateral breast cancer or IBTR. Initial or delayed PM was associated with a reduced risk of IBTR but not with overall survival or breast cancer–specific mortality.Conclusions: The study findings suggest that PSO should be offered to all patients with BRCA1/2 breast cancer who undergo surgery with curative intent to reduce risk of death. In particular, PSO should be offered to patients with the BRCA1 variant at the time of breast surgery.
- 1 December 2023
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 158 (12) , 1275-1284
Open AccessProphylactic Salpingo-Oophorectomy and Survival After BRCA1/2 Breast Cancer Resection
Importance: Few studies have investigated whether prophylactic salpingo-oophorectomy (PSO) for patients with previously resected breast cancer who carry pathogenic germline BRCA1 or BRCA2 variants is associated with a reduced risk of cancer-specific death.Objective: To assess the association of PSO and prophylactic mastectomy (PM) with prognosis after quadrantectomy or mastectomy as primary treatment for patients with BRCA1 or BRCA2 breast cancer.Design, Setting, and Participants: This retrospective cohort study was performed in a single-institution, tertiary referral center. Consecutive patients with invasive breast cancer treated surgically between 1972 and 2019 were recruited and followed up prospectively after they were found to carry the BRCA1 or BRCA2 gene variant. The data analysis was performed between April 2022 and July 2023.Exposure: Following breast surgery, some patients underwent PSO, PM, or both, whereas others did not.Main Outcomes and Measures: The primary study end point was overall survival as measured by the Kaplan-Meier method. Secondary end points were crude cumulative incidence of breast cancer–specific mortality, ipsilateral breast tumor recurrence (IBTR), contralateral breast cancer, ovarian cancer, and ovarian cancer–specific mortality.Results: Of 480 patients included in the cohort (median age at initial surgery, 40.0 years; IQR, 34.0-46.0 years), PSO was associated with a significantly reduced risk of death (hazard ratio [HR], 0.40; 95% CI, 0.25-0.64; P < .001). This reduction was most evident for patients carrying the BRCA1 variant (HR, 0.35; 95% CI, 0.20-0.63; P = .001), those with triple-negative disease (HR, 0.21; 95% CI, 0.09-0.46; P = .002), and those with invasive ductal carcinoma (HR, 0.51; 95% CI, 0.31-0.84; P = .008). Prophylactic salpingo-oophorectomy was not associated with risk of contralateral breast cancer or IBTR. Initial or delayed PM was associated with a reduced risk of IBTR but not with overall survival or breast cancer–specific mortality.Conclusions: The study findings suggest that PSO should be offered to all patients with BRCA1/2 breast cancer who undergo surgery with curative intent to reduce risk of death. In particular, PSO should be offered to patients with the BRCA1 variant at the time of breast surgery.
- 15 October 2020
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 276 (5) , e544-e552
Sentinel Node Biopsy Alone or With Axillary Dissection in Breast Cancer Patients After Primary Chemotherapy: Long-Term Results of a Prospective Interventional Study
Objective: To ascertain, in cN0/1 breast cancer patients given primary chemotherapy followed by sentinel node biopsy (SNB), whether SNB alone is adequate axillary treatment if the sentinel nodes (SNs) are clear (pN0). Summary Background Data: 2020 guidelines do not recommend SNB in most cN1 patients with clear SNs after primary chemotherapy because the high SNB false negative rate might lead to poorer outcomes. Methods: We prospectively assigned SNB after primary chemotherapy to 353 consecutive cT2 cN0/1 patients, median age 47 years (range 22-76) treated from 2007 to 2015. If the SNs were pN0, patients generally received no further axillary treatment (SNB only); if the SNs were pN1, completion axillary dissection (AD) (SNB + AD) was usually performed. Primary outcomes were overall (OS) and disease-free (DFS) survival in SNB only versus SNB + AD patients, assessed by Kaplan-Meier and compared using log-rank test, with use of propensity scores to account for bias due to nonrandom assignment to SNB versus SNB + AD. Results: Median follow-up was 108 months, interquartile range 66 to 136. OS and DFS did not differ significantly between the groups by propensity score- weighted comparison: 10-year OS 89% [95% confidence interval (CI): 81%- 99%] in SNB only patients versus 86% (95%CI: 78%–95%) in SNB + AD patients; 10-year DFS 79% (95%CI: 68%–92%) versus 69% (95%CI: 58%–81%). No SNB-only patient developed axillary failure. Conclusions: cT2 cN0/1 patients whose SNs are disease-free (pN0) after primary chemotherapy can be offered SNB (with no further axillary treatment if the SNs are negative), irrespective of axillary status beforehand, without affecting OS or DFS.
- 15 October 2020
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 276 (5) , e544-e552
Sentinel Node Biopsy Alone or With Axillary Dissection in Breast Cancer Patients After Primary Chemotherapy: Long-Term Results of a Prospective Interventional Study
Objective: To ascertain, in cN0/1 breast cancer patients given primary chemotherapy followed by sentinel node biopsy (SNB), whether SNB alone is adequate axillary treatment if the sentinel nodes (SNs) are clear (pN0). Summary Background Data: 2020 guidelines do not recommend SNB in most cN1 patients with clear SNs after primary chemotherapy because the high SNB false negative rate might lead to poorer outcomes. Methods: We prospectively assigned SNB after primary chemotherapy to 353 consecutive cT2 cN0/1 patients, median age 47 years (range 22-76) treated from 2007 to 2015. If the SNs were pN0, patients generally received no further axillary treatment (SNB only); if the SNs were pN1, completion axillary dissection (AD) (SNB + AD) was usually performed. Primary outcomes were overall (OS) and disease-free (DFS) survival in SNB only versus SNB + AD patients, assessed by Kaplan-Meier and compared using log-rank test, with use of propensity scores to account for bias due to nonrandom assignment to SNB versus SNB + AD. Results: Median follow-up was 108 months, interquartile range 66 to 136. OS and DFS did not differ significantly between the groups by propensity score- weighted comparison: 10-year OS 89% [95% confidence interval (CI): 81%- 99%] in SNB only patients versus 86% (95%CI: 78%–95%) in SNB + AD patients; 10-year DFS 79% (95%CI: 68%–92%) versus 69% (95%CI: 58%–81%). No SNB-only patient developed axillary failure. Conclusions: cT2 cN0/1 patients whose SNs are disease-free (pN0) after primary chemotherapy can be offered SNB (with no further axillary treatment if the SNs are negative), irrespective of axillary status beforehand, without affecting OS or DFS.
- Open Access
- 23 October 2018
- Published by Elsevier in Annals of Oncology
- Vol. 29 (suppl_8) , viii80
Use of red clover in premenopausal breast cancer patients receiving hormonal adjuvant treatment: Biological and clinical implications from a randomized clinical trial
Background: Premenopausal women with breast cancer (BC) experience early onset of treatment-induced menopausal syndrome with adjuvant hormone therapy (HT). Isoflavones in the red clover (RC) are biologically active agents providing a source of rapidly available phytoestrogens acting as natural selective estrogen receptor modulators. Aims of the study are: to improve quality of life reducing menopausal symptoms from HT in BC premenopausal women and preventing weight gain and metabolic syndrome with personal lifestyle intervention; to evaluate in vitro safety profile of RC used in combination with adjuvant anti-estrogenic HT.
- 23 October 2018
- Published by Elsevier in Annals of Oncology
- Vol. 29 (suppl_8) , viii80
Open AccessUse of red clover in premenopausal breast cancer patients receiving hormonal adjuvant treatment: Biological and clinical implications from a randomized clinical trial
Background: Premenopausal women with breast cancer (BC) experience early onset of treatment-induced menopausal syndrome with adjuvant hormone therapy (HT). Isoflavones in the red clover (RC) are biologically active agents providing a source of rapidly available phytoestrogens acting as natural selective estrogen receptor modulators. Aims of the study are: to improve quality of life reducing menopausal symptoms from HT in BC premenopausal women and preventing weight gain and metabolic syndrome with personal lifestyle intervention; to evaluate in vitro safety profile of RC used in combination with adjuvant anti-estrogenic HT.
- 1 November 2017
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 43 (11) , 2012-2020
Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study
- 1 November 2017
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 43 (11) , 2012-2020
Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study
- Open Access
- 4 September 2015
- Published by Springer Nature in SpringerPlus
- Vol. 4 (1) , 482
Can titanium mesh influence local recurrence management after implant-based breast reconstruction?
TiLOOP® Bra is a permanent titanium-coated polypropylene mesh currently used in post-mastectomy breast reconstruction with implants. This mesh is generally presented as inducing low-grade inflammatory reactions, but only few reports focused on its possible side effects. In the case described here, the use of the mesh led to minor clinical problems that needed to be clinically and surgically managed at the same time as a local relapse. A patient with high-grade ductal carcinoma in situ underwent primary surgery (nipple-sparing mastectomy and one-stage reconstruction using the TiLOOP® Bra mesh) and was subsequently referred for radiological and clinical investigation when various nodules became apparent during a follow-up physical examination. Prior to the histopathological proof, the diagnosis of local recurrence was complicated by the occurrence of an extensive granulomatous reaction in the fixation areas along with mild inflammatory changes scattered on the surface of the mesh. This case illustrates a side effect of titanium-coated permanent mesh in immediate implant-based reconstruction, i.e. the formation of granulomas in the inframammary fold, probably in the area where the mesh had been folded or fixed. We propose a safer technical approach to avoid the problem and a clinical management strategy for patients at high risk of local recurrence who develop granuloma-like nodules. A surgical technique is suggested to prevent granuloma formation. If, however, subcutaneous nodules that may be local recurrences do appear, they should not be interpreted by default as a granulomatous reaction, but should be fully investigated and possibly excised.
- 4 September 2015
- Published by Springer Nature in SpringerPlus
- Vol. 4 (1) , 482
Open AccessCan titanium mesh influence local recurrence management after implant-based breast reconstruction?
TiLOOP® Bra is a permanent titanium-coated polypropylene mesh currently used in post-mastectomy breast reconstruction with implants. This mesh is generally presented as inducing low-grade inflammatory reactions, but only few reports focused on its possible side effects. In the case described here, the use of the mesh led to minor clinical problems that needed to be clinically and surgically managed at the same time as a local relapse. A patient with high-grade ductal carcinoma in situ underwent primary surgery (nipple-sparing mastectomy and one-stage reconstruction using the TiLOOP® Bra mesh) and was subsequently referred for radiological and clinical investigation when various nodules became apparent during a follow-up physical examination. Prior to the histopathological proof, the diagnosis of local recurrence was complicated by the occurrence of an extensive granulomatous reaction in the fixation areas along with mild inflammatory changes scattered on the surface of the mesh. This case illustrates a side effect of titanium-coated permanent mesh in immediate implant-based reconstruction, i.e. the formation of granulomas in the inframammary fold, probably in the area where the mesh had been folded or fixed. We propose a safer technical approach to avoid the problem and a clinical management strategy for patients at high risk of local recurrence who develop granuloma-like nodules. A surgical technique is suggested to prevent granuloma formation. If, however, subcutaneous nodules that may be local recurrences do appear, they should not be interpreted by default as a granulomatous reaction, but should be fully investigated and possibly excised.
- 20 May 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (11) , 1358-1364
Omission of radiotherapy in elderly patients with early breast cancer: 15-Year results of a prospective non-randomised trial
- 20 May 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (11) , 1358-1364
Omission of radiotherapy in elderly patients with early breast cancer: 15-Year results of a prospective non-randomised trial
- 12 February 2015
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 42 (6) , 818-830
18F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study
We evaluated whether 18F-3′-deoxy-3′-fluorothymidine positron emission tomography (FLT PET) can predict the final postoperative histopathological response in primary breast cancer after the first cycle of neoadjuvant chemotherapy (NCT).
- 12 February 2015
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 42 (6) , 818-830
18F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study
We evaluated whether 18F-3′-deoxy-3′-fluorothymidine positron emission tomography (FLT PET) can predict the final postoperative histopathological response in primary breast cancer after the first cycle of neoadjuvant chemotherapy (NCT).